Our study suggested that AGN and decursin might be effective in inducing cytotoxicity by targeting Myc, a critical downstream molecule of BCR signaling, and their combination with Myc inhibitors could provide synergistic chemotherapeutic effects for the treatment of B-cell lymphomas. The gene discussed is BCR; the disease is B-cell non-Hodgkin lymphoma.